Ibrutinib-Associated Cardiac Tamponade with Concurrent Antiplatelet Therapy

Ibrutinib is approved for the first-line treatment of chronic lymphocytic leukemia (CLL). A well-known side effect of ibrutinib therapy is increased bleeding risk, which ranges from mild mucocutaneous bleeding to rarely life-threatening hemorrhage. The increased bleeding tendency associated with ibr...

Descripción completa

Detalles Bibliográficos
Autores principales: Miatech, Jennifer L., Hughes, John H., McCarty, Dillon K., Stagg, M. Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139853/
https://www.ncbi.nlm.nih.gov/pubmed/32280549
http://dx.doi.org/10.1155/2020/4282486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139853/
https://www.ncbi.nlm.nih.gov/pubmed/32280549
http://dx.doi.org/10.1155/2020/4282486

Ejemplares similares